Skip to main content
. Author manuscript; available in PMC: 2009 Aug 1.
Published in final edited form as: Cancer Res. 2008 Aug 1;68(15):6084–6091. doi: 10.1158/0008-5472.CAN-07-6854

Figure 5.

Figure 5

Correlations between PIK3CA mutations and patient survival. No significant differences in RFS (A and B) or OS (C and D) times were found after adjuvant tamoxifen therapy between patients with early-stage PIK3CA wild-type hormone receptor–positive breast tumors and those with PIK3CA-mutant breast tumors.